"Kallikreins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
| Descriptor ID |
D007610
|
| MeSH Number(s) |
D08.811.277.656.300.760.442 D08.811.277.656.959.350.442 D12.776.124.125.597 D23.119.597
|
| Concept/Terms |
Kallikreins- Kallikreins
- Kalliginogenase
- Kallikrein
- Kininogenase
- Callicrein
- Kallidinogenase
- Kinin-Forming Enzyme
- Enzyme, Kinin-Forming
- Kinin Forming Enzyme
|
Below are MeSH descriptors whose meaning is more general than "Kallikreins".
Below are MeSH descriptors whose meaning is more specific than "Kallikreins".
This graph shows the total number of publications written about "Kallikreins" by people in this website by year, and whether "Kallikreins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 3 | 9 | 12 |
| 2018 | 5 | 5 | 10 |
| 2019 | 3 | 2 | 5 |
| 2020 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Kallikreins" by people in Profiles.
-
Kallikreins emerge as new regulators of viral infections. Cell Mol Life Sci. 2021 Nov; 78(21-22):6735-6744.
-
Search for Non-Protein Protease Inhibitors Constituted with an Indole and Acetylene Core. Molecules. 2021 Jun 23; 26(13).
-
COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies. Mol Biol Rep. 2021 Mar; 48(3):2917-2928.
-
SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung. Elife. 2021 03 08; 10.
-
Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19. Viruses. 2021 02 16; 13(2).
-
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. Trials. 2021 Jan 20; 22(1):71.
-
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials. 2020 Dec 09; 21(1):1005.
-
Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1. Sci Signal. 2020 11 24; 13(659).
-
SARS-CoV-2 and interferon blockade. Mol Med. 2020 11 09; 26(1):103.
-
The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. Peptides. 2021 01; 135:170428.